Bortether 2 mg Injection

Bortether 2 mg Injection contains bortezomib 2 mg, a proteasome inhibitor used as an anticancer medicine. It is used in the treatment of multiple myeloma and mantle cell lymphoma in specific clinical settings. The injection is administered intravenously or subcutaneously by a qualified healthcare professional.

BUY NOW

Bortezomib works by inhibiting proteasomes, cellular structures that help regulate protein breakdown and cell survival. This action can interfere with the growth and survival of abnormal plasma cells and lymphoma cells. Bortether 2 mg Injection is marketed by Therdose Pharma Pvt Ltd and is supplied as a 2 mg vial. Treatment schedule and dosage are determined by the treating oncologist according to the patient’s condition and prescribed chemotherapy protocol.

Technical Specification

Specification Details
Active Ingredient Bortezomib
Strength 2 mg
Dosage Form Injection
Therapeutic Class Proteasome Inhibitor
Route of Administration Intravenous / Subcutaneous
Pack Size 1 vial

Product Also Known As

Bortether 2 mg Injection, Bortether 2mg Injection, Bortezomib 2 mg Injection, Bortezomib 2mg Injection, Bortezomib Anticancer Injection, Bortezomib Multiple Myeloma Injection, Proteasome Inhibitor Injection